Freeman 1968.

Methods	Allocation: randomly assigned, random code not broken to the end of study. Blindness: double (identical capsules). Design: 2 parallel groups, single centre. Duration: 12 weeks (preceded by 4 weeks washout). Analysis: intention‐to‐treatnot performed in the trial. Country: USA.
Participants	Diagnosis: schizophrenia, no further details. N=41. Age: mean 30 years. Sex: M 14, F 27. Setting: hospital. History: majority of cases undifferentiated and paranoid. Inclusion: duration of present illness of not more than 2 years and hospital admissions not longer than 5 years.
Interventions	1. Trifluoperazine: dose 15 mg/day (first week), 30 mg/day (second week), maximum 45 mg/day (mean 26 mg). N=20. 2. SKF 14336: dose 200 mg/day (first week), 400 mg/day (second week), maximum 600 mg/day (mean 385 mg). N=21.
Outcomes	Global state: (global judgement of the psychiatrists). Use of antiparkinson agents. Side effects. Leaving the study early. Side effects: (abnormal laboratory tests). Unable to use ‐ Mental state: (BPRS; IMPS ‐ only graphs).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate